Drug Profile
Glycopyrrolate inhalation - Novartis/Sosei R&D
Alternative Names: AD-237; Enurev Breezhaler; Inhaled glycopyrrolate; Inhaled glycopyrronium bromide; NVA-237; Seebri Breezhaler; Seebri Inhalation Capsules; Seebri Neohaler; SeebriBreezhaler; Tovanor BreezhalerLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Arakis Ltd; Vectura
- Developer Novartis; Sumitomo Pharma America
- Class Antiasthmatics; Antispasmodics; Antiulcers; Pyrrolidines; Quaternary ammonium compounds; Skin disorder therapies; Small molecules
- Mechanism of Action Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Chronic obstructive pulmonary disease
- Phase II Asthma
Most Recent Events
- 23 Jun 2022 Phase-II clinical trials in Asthma (In children) in Spain, Hungary (Inhalation) (EudraCT2021-004972-32) (NCT05222529)
- 04 Feb 2022 Novartis plans a phase II trial for Asthma (In children) in undisclosed locations (Inhalation, Powder) in May 2022 (NCT05222529) (EudraCT2021-004972-32)
- 05 Jan 2022 Covis Pharma entered into a Distribution Agreement with Novartis Pharmaceuticals Canada